Finn A. Clinical Trials of Influenza Vaccines: Special Challenges. Methods Mol Biol. 2018;1836:567-573
Clinical trials of vaccines differ from those of drugs both practically and ethically. Influenza vaccine trials pose additional challenges which flow from the seasonality of the disease and vaccine programmes and the changeability of circulating strains and epidemic size. Serological correlates are widely used in evaluating influenza vaccines but interpreting such responses is also difficult. Development and testing of vaccines for deployment in an influenza pandemic combines all these obstacles with extreme unpredictability, enormous urgency and the need for very large numbers of doses. Advances in manufacturing technology, diagnostics, identification of stable protective antigens and epitopes, new adjuvants and improved understanding of indirect and downstream effects may help to alleviate these difficulties in the future.
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 10 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 10 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 10 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 11 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 11 hours ago
[Go Top] [Close Window]


